【摘要】 目的观察2型糖尿病合并高血压(DMEH)患者血清基质金属蛋白酶-2(MMP-2)及其组织抑制因子-1(TIMP-1)的水平及罗格列酮治疗后的变化。方法将T2DM患者分成三组:(1)T2DM无合并症(即单纯T2DM),52例(男25例,女27例);(2)T2DM合并高血压非罗格列酮治疗组25例(男13例,女12例);(3)T2DM合并高血压罗格列酮治疗组25例(男12例,女13例)。采用酶联免疫吸附(ELISA)法测定血清MMP-2及其组织抑制因子-1(TIMP-1)和实验室相关指标,观察罗格列酮治疗前后MMP-2、TIMP-1水平变化及与非罗格列酮治疗组之间变化的差别。结果应用罗格列酮治疗组治疗16 wk后的血清MMP-2、TIMP-1水平分别为29.1±3.3和488.6±103.2 ng/ml,较治疗前水平MMP-2(24.3±2.6)明显升高,P<0.05;而TIMP-1水平较治疗前(566.1±111.3)则明显降低P<0.01。结论罗格列酮治疗除能改善血糖及血压外,还可升高MMP-2和降低TIMP-1水平。更多还原

【Abstract】 Objective To observe the levels of serum MMP-2 and TIMP-1,and the changes of rosiglitazone in the patients with diabetic hypertension.Methods 102 cases of patients with diabetes type-2 were divided into 3 groups:(1) 52cases with single T2DM(25 males,27 females);(2) 25 cases of T2DM with diabetic hypertension but without rosiglitazone treatment(13males,12females);(3)25 cases of T2DM with both diabetic hypertension and rosiglitazone treatment(12 males,13 females).ELISA method was adopted to determine the levels of MMP-2 and TIMP-1,the differences of the changes of MMP-2 and TIMP-1 between pre-use and postuse of rosiglitazone were observed.pre-use and post-use of rosiglitazone were observed.Results 16 wk after the treatment by rosiglitazone,the levels of MMP-2 and TIMP-1 were(29.1±3.3) and(488.6±103.2)ng/ml respectively,the level of MMP-2 was significantly higher than that before treatment(24.3±2.6)(P<0.05),while the level of TIMP-1 was significantly lower than that before treatment(566.1±111.3)(P<0.01).Conclusion Rosiglitazone can not only improve blood sugar and blood pressure,but also raise the level of MMP-2 and reduce the level of TIMP-1.更多还原